/

SILO

Silo Pharma, Inc.After hours

1.20−0.02 −1.64%USD

NasdaqCM · as of Oct 14, 16:00 ET · 15m delayAfter hours 1.25 +4.17%

Open

1.22

Prev close

1.22

Day range

1.201.26

52-week range

1.1010.43

Volume

64.78K0.66×

Mkt cap

2.46M

P/E ttm

—

Fwd P/E

-1.71

EPS ttm

-4.26

Div yield

0.00%

Earnings

—

From 52w high

−88.49%

Price Chart

Yahoo Finance · delayed

SILOOct 14, 2026O 1.22H 1.25L 1.20C 1.20−0.02 (−1.64%)Vol 64.78K

SMA 502.30
SMA 2004.82

1Y change −87.26% since Oct 13, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

SILO Silo Pharma, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −16.67%
1 month: −42.03%
3 months: −75.38%
6 months: −80.49%
Year to date: −76.47%
1 year: −87.08%

Valuation & ownership

Market cap: 2.46M
Enterprise value: −3.29M
P/E (ttm): —
Forward P/E: -1.71
PEG ratio: —
Price / book: 0.28
Price / sales (ttm): 45.56
EV / EBITDA: 0.74
EPS (ttm): -4.26
EPS (forward): -0.7000
Beta (5y monthly): 0.91
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 2.05M
Float: 1.57M
Short % of float: 2.18%
Short ratio (days): 0.67
Held by insiders: 8.87%
Held by institutions: 8.16%
Avg volume (3m): 98.44K
50-day average: 2.37
200-day average: 4.84
52-week change: −87.08%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): oversold 17.1
vs 50-day SMA: −47.79%
vs 200-day SMA: −75.12%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 13.32%
Realised vol (20d, ann.): 83.6%
From 52-week high: −88.49%
From 52-week low: +9.09%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 54.08K
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: -14.77%
Operating margin: -8250.46%
Profit margin: 0.00%

DES

About Silo Pharma, Inc.

Yahoo Finance profile

Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. In addition, the company is developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Sector: Healthcare
Industry: Biotechnology
Employees: 3
Headquarters: Sarasota, FL, United States
Website: silopharma.com
Officers: Mr. Eric Weisblum Chairman, President & CEO
Mr. Daniel E. Ryweck Chief Financial Officer

SEAS

Seasonality · SILO

2021–2026 · monthly returns

Strongest month Jan +26.81%Weakest month Aug −14.71%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	1.5	6.4	-1.9	22.8	-3.2	-3.3	-32.5	-40.8	-39.1	-20.5			−76.5%
2025	80.9	-15.8	-13.7	-35.9	-40.8	41.9	23.7	-19.4	9.9	-21.4	-14.2	-26.9	−61.8%
2024	7.6	2.6	22.6	-5.7	13.2	-51.9	106.0	-43.2	-6.0	2.7	-11.5	-11.0	−38.2%
2023	-17.7	-19.0	-6.2	2.4	1.8	-6.3	4.4	-11.6	-11.7	-9.6	2.6	-7.1	−57.1%
2022	36.4	-2.6	10.5	-24.8	-8.2	-24.1	25.5	-5.1	-17.9	-28.4	-7.8	-5.4	−53.0%
2021		-11.2	-6.5	-6.9	-9.3	2.0	-36.8	5.7	16.8	2.6	-14.0	-16.9	−59.0%

INSD

Insider Activity · SILO

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Dec 14, 2025	Weisblum EricChief Executive Officer	Purchase at price 0.41 - 0.42 per share.	5K	$2.08K
Nov 20, 2025	Weisblum EricChief Executive Officer	Purchase at price 0.36 - 0.37 per share.	2K	$735
Nov 18, 2025	Weisblum EricChief Executive Officer	Purchase at price 0.40 per share.	12K	$4.85K
May 26, 2025	Weisblum EricChief Executive Officer	Purchase at price 0.43 per share.	10K	$4.33K
Dec 12, 2024	Weisblum EricChief Executive Officer	Purchase at price 0.84 per share.	2.5K	$2.10K
Nov 21, 2024	Weisblum EricChief Executive Officer	Purchase at price 0.90 - 0.95 per share.	5K	$4.63K

SILO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

SILO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Silo Pharma, Inc.

Seasonality · SILO

Insider Activity · SILO

Congress Trades · SILO

Investors Holding SILO

Investors Holding SILO

Congress Trades · SILO

Insider Activity · SILO

Seasonality · SILO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Silo Pharma, Inc.

Earnings & Dividends

News